Biotech Biggie Amgen To Pay $762 Million Over Improper Marketing Of Anemia Drug

The world’s largest biotechnology company pleaded guilty in federal court today for improper marketing practices involving its anemia drug Aranesp, and says it will pay $762 million in a combination of civil settlements and criminal fines. It won’t lose out on any federal business or contracts, however, which would’ve been a veritable death knell for the company. [More]


A new meta-analysis showed that popular anemia drugs Aranesp and Procrit increase the risk of death in cancer patients by 10 percent, a statistically significant number. [NYT]